GoKawiilFDA to add eye-damage warning label to Ozempic, Wegovy, Zepbound and Mounjaro
The FDA issued a drug safety communication requiring makers of GLP-1 drugs—including Ozempic, Wegovy, Zepbound and Mounjaro—to add a warning about a possible link to NAION, a rare condition that restricts blood flow to the optic nerve and can cause sudden, permanent vision loss. The agency says the exact mechanism is unknown, and the condition's rarity, combined with overlapping risk factors common among GLP-1 users like diabetes and high blood pressure, makes confirming a direct causal link difficult.
GoKawiil's interpretation of the reporting above, not reported fact.
The decision suggests regulators see enough signal in available data—including a 2024 Harvard study published in JAMA Ophthalmology showing higher NAION rates among semaglutide users—to warrant caution, even without conclusive proof of causation. This could prompt doctors and patients to weigh new risks against the drugs' benefits for diabetes and obesity treatment, and may invite further scrutiny or lawsuits regarding GLP-1 safety.
- FDA will require GLP-1 drug labels to warn about potential NAION risk, a rare cause of permanent vision loss.
- The mechanism linking GLP-1 drugs to NAION remains unknown, and risk factors overlap with conditions common in GLP-1 users.
- A 2024 Harvard study found notably higher NAION rates among diabetes and obesity patients taking semaglutide compared to those on non-GLP-1 drugs.
Source: arstechnica.com, 2026-11-10
Published there as: “FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.